

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/061415 A1

(51) International Patent Classification:

C07D 487/08 (2006.01) C07D 239/00 (2006.01)
C07D 487/22 (2006.01) C07D 241/00 (2006.01)
C07D 498/18 (2006.01) C07D 209/00 (2006.01)
A61K 31/505 (2006.01) C07D 273/00 (2006.01)
A61P 35/00 (2006.01) C07D 221/00 (2006.01)
C07D 259/00 (2006.01)

(21) International Application Number:

PCT/EP2005/056606

(22) International Filing Date:

8 December 2005 (08.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/634,291 8 December 2004 (08.12.2004) US
04106384.3 8 December 2004 (08.12.2004) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FREYNE, Eddy,
Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V.,


Turnhoutseweg 30, B-2340 Beerse (BE). WILLEMS, Marc [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). EMBRECHTS, Werner, Constant, Johan [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN EMELEN, Kristof [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VAN BRANDT, Sven, Franciscus, Anna [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). ROMBOUTS, Frederik, Jan, Rita [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: 2,4 (4,6) PYRIMIDINE DERIVATIVES



(57) Abstract: The present invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z¹ and Z² represent NH; Y represents -C₃₋₉alkyl-, -C₃₋₉alkenyl-, -C₁₋₅alkyl-NR⁶-C₁₋₅alkyl-, -C₁₋₅alkyl-NR⁷-CO-C₁₋₅alkyl-, -C₁₋₆alkyl-CO-NH-, -C₁₋₆alkyl-NH-CO-, -C₁₋₂alkyl-CO-Het¹⁰-CO-, -C₁₋₃alkyl-NH-CO-Het¹-, -Het⁴-C₁₋₃alkyl-CO-NH-C₁₋₃alkyl-, -C₁₋₂alkyl-NH-CO-L¹-NH-, -NH-CO-L²-NH-, -C₁₋₂alkyl-CO-NH-L³-CO-, -C₁₋₂alkyl-NH-CO-L¹-NH-CO-C₁₋₃alkyl-, -C₁₋₂alkyl-CO-NH-L³-CO-NH-C₁₋₃alkyl-, -C₁₋₂alkyl-NR¹¹-CH₂-CO-NH-C₁₋₃alkyl-,

Het⁵-CO-C₁₋₂alkyl-, -C₁₋₅alkyl-CO-NH-C₁₋₃alkyl-CO-NH-, -C₁₋₅alkyl-NR¹³-CO-C₁₋₃alkyl-NH-, -C₁₋₃alkyl-NH-CO-Het²⁷-CO-, or -C₁₋₃alkyl-CO-Het²⁸-CO-NH-; X¹ represents a direct bond, O, -O-C₁₋₂alkyl-, -CO-C₁₋₂alkyl-, -NR¹⁶-C₁₋₂alkyl-, -CO-NR¹⁷-, Het²³-C₁₋₂alkyl- or C₁₋₂alkyl; X² represents a direct bond, O, -O-C₁₋₂alkyl-, -CO-C₁₋₂alkyl-, -NR¹⁸-C₁₋₂alkyl-, -CO-NR¹⁹-, Het²⁴-C₁₋₂alkyl- or C₁₋₂alkyl; R¹ and R⁵ each independently represent hydrogen, halo, C₁₋₆alkyloxy- or C₁₋₆alkyloxy- substituted with Het¹ or C₁₋₄alkyloxy-; R² and R⁴ each independently represent hydrogen or halo; R³ represents hydrogen or cyano; R⁶, R⁷, R¹³, R¹⁷ and R¹⁹ represent hydrogen; R¹¹ represents hydrogen or C₁₋₄alkyl; R¹⁶ and R¹⁸ represent hydrogen, C₁₋₄alkyl or Het¹⁷-C₁₋₄alkyl; L¹, L² and L³ each independently represents C₁₋₈alkyl optionally substituted with one or where possible two or more substituents selected from phenyl, methylsulfide, cyano, polyhaloC₁₋₄alkyl-phenyl-, C₁₋₄alkyloxy, pyridinyl, mono- or di(C₁₋₄alkyl)-amino- or C₃₋₆cycloalkyl; Het¹, Het², Het¹⁷ each independently represent morpholinyl, oxazolyl, isoxazolyl, or piperazinyl; Het³, Het⁴, Het⁵ each independently represent morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl; Het¹⁰ represents piperazinyl, piperidinyl, pyrrolidinyl or azetidyl; Het²² represents morpholinyl, oxazolyl, isoxazolyl or piperazinyl wherein said Het²² is optionally substituted with C₁₋₄alkyl; Het²³ and Het²⁴ each independently represent a heterocycle selected from pyrrolidinyl, piperazinyl or piperidinyl wherein said Het²³ or Het²⁴ are optionally substituted with Het²²-carbonyl; Het²⁷ and Het²⁸ each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl.

WO 2006/061415 A1



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.